BACKGROUND: Human monkeypox is an emerging smallpox-like illness that was identified for the first time in the United States during an outbreak in 2003. Knowledge of the clinical manifestations of monkeypox in adults is limited, and clinical laboratory findings have been unknown. METHODS: Demographic information; medical history; smallpox vaccination status; signs, symptoms, and duration of illness, and laboratory results (hematologic and serum chemistry findings) were extracted from medical records of patients with a confirmed case of monkeypox in the United States. Two-way comparisons were conducted between pediatric and adult patients and between patients with and patients without previous smallpox vaccination. Bivariate and multivariate analyses of risk factors for severe disease (fever [temperature, > or =38.3 degrees C] and the presence of rash [> or =100 lesions]), activity and duration of hospitalization, and abnormal clinical laboratory findings were performed. RESULTS: Of 34 patients with a confirmed case of monkeypox, 5 (15%) were defined as severely ill, and 9 (26%) were hospitalized for >48 h; no patients died. Previous smallpox vaccination was not associated with disease severity or hospitalization. Pediatric patients (age, < or =18 years) were more likely to be hospitalized in an intensive care unit. Nausea and/or vomiting and mouth sores were independently associated with a hospitalization duration of >48 h and with having > or =3 laboratory tests with abnormal results. CONCLUSION: Monkeypox can cause a severe clinical illness, with systemic signs and symptoms and abnormal clinical laboratory findings. In the appropriate epidemiologic context, monkeypox should be included in the differential diagnosis for patients with unusual vesiculopustular exanthems, mucosal lesions, gastrointestinal symptoms, and abnormal hematologic or hepatic laboratory findings. Clinicians evaluating a rash illness consistent with possible orthopoxvirus infection should alert public health officials and consider further evaluation.
BACKGROUND:Human monkeypox is an emerging smallpox-like illness that was identified for the first time in the United States during an outbreak in 2003. Knowledge of the clinical manifestations of monkeypox in adults is limited, and clinical laboratory findings have been unknown. METHODS: Demographic information; medical history; smallpox vaccination status; signs, symptoms, and duration of illness, and laboratory results (hematologic and serum chemistry findings) were extracted from medical records of patients with a confirmed case of monkeypox in the United States. Two-way comparisons were conducted between pediatric and adult patients and between patients with and patients without previous smallpox vaccination. Bivariate and multivariate analyses of risk factors for severe disease (fever [temperature, > or =38.3 degrees C] and the presence of rash [> or =100 lesions]), activity and duration of hospitalization, and abnormal clinical laboratory findings were performed. RESULTS: Of 34 patients with a confirmed case of monkeypox, 5 (15%) were defined as severely ill, and 9 (26%) were hospitalized for >48 h; no patients died. Previous smallpox vaccination was not associated with disease severity or hospitalization. Pediatric patients (age, < or =18 years) were more likely to be hospitalized in an intensive care unit. Nausea and/or vomiting and mouth sores were independently associated with a hospitalization duration of >48 h and with having > or =3 laboratory tests with abnormal results. CONCLUSION: Monkeypox can cause a severe clinical illness, with systemic signs and symptoms and abnormal clinical laboratory findings. In the appropriate epidemiologic context, monkeypox should be included in the differential diagnosis for patients with unusual vesiculopustular exanthems, mucosal lesions, gastrointestinal symptoms, and abnormal hematologic or hepatic laboratory findings. Clinicians evaluating a rash illness consistent with possible orthopoxvirus infection should alert public health officials and consider further evaluation.
Authors: Megan M McCausland; Mohammed Rafii-El-Idrissi Benhnia; Lindsay Crickard; John Laudenslager; Steven W Granger; Tomoyuki Tahara; Ralph Kubo; Lilia Koriazova; Shinichiro Kato; Shane Crotty Journal: Antivir Ther Date: 2010
Authors: Julie Dyall; Reed F Johnson; Dar-Yeong Chen; Louis Huzella; Dan R Ragland; Daniel J Mollura; Russell Byrum; Richard C Reba; Gerald Jennings; Peter B Jahrling; Joseph E Blaney; Jason Paragas Journal: J Infect Dis Date: 2011-10-19 Impact factor: 5.226
Authors: Christina L Hutson; Nadia Gallardo-Romero; Darin S Carroll; Johanna S Salzer; Jessica D Ayers; Jeff B Doty; Christine M Hughes; Yoshi Nakazawa; Paul Hudson; Nishi Patel; M S Keckler; Victoria A Olson; Tamas Nagy Journal: J Am Assoc Lab Anim Sci Date: 2019-05-29 Impact factor: 1.232
Authors: Elizabeth A Falendysz; Angela M Londoño-Navas; Carol U Meteyer; Nicola Pussini; Juan G Lopera; Jorge E Osorio; Tonie E Rocke Journal: J Wildl Dis Date: 2014-04-29 Impact factor: 1.535
Authors: Scott Parker; Jill Schriewer; Christina Oberle; Alice Robertson; Randall Lanier; George Painter; R Mark Buller Journal: Antivir Ther Date: 2008
Authors: Mary G Reynolds; Whitni B Davidson; Aaron T Curns; Craig S Conover; Gregory Huhn; Jeffrey P Davis; Mark Wegner; Donita R Croft; Alexandra Newman; Nkolika N Obiesie; Gail R Hansen; Patrick L Hays; Pamela Pontones; Brad Beard; Robert Teclaw; James F Howell; Zachary Braden; Robert C Holman; Kevin L Karem; Inger K Damon Journal: Emerg Infect Dis Date: 2007-09 Impact factor: 6.883